The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Mechanisms of action of mycophenolate mofetil
Abstract
Mycophenolate mofetil (MMF, CellCept®) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5′‘monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation. MPA also inhibits the glycosylation and expression of adhesion molecules, and the recruitment of lymphocytes and monocytes into sites of inflammation. MPA depletes tetrahydrobiopterin and decreases the production of nitric oxide by inducible NO synthase without affecting the activity of constitutive NO synthases. Activated macrophages produce NO and superoxide, which combine to generate tissue-damaging peroxynitrite. By these two mechanisms MMF exerts anti-inflammatory activity. Unlike calcineurin inhibitors, MMF is not nephrotoxic and does not induce the production of TGF β, which is fibrogenic. MMF does not increase blood pressure, cholesterol levels or triglyceride levels in recipients. MMF reduces acute and chronic rejection in allograft recipients and is efficacious in some nephropathies. Evidence is accumulating that MMF may have clinical utility in some autoimmune disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mycophenolate mofetil (MMF), prodrug of mycophenolic acid, preferentially inhibits type II IMPDH, suppressing T and B cells proliferation (74).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [74]
Citations
Cites
Nitric oxide: physiology, pathophysiology, and pharmacology.
Moncada, S., Palmer, R. M., & Higgs, E. A. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06663-3 · Cited by 15,525
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,581
ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITY
Giblett, E. R., Anderson, J. E., Cohen, F., et al. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92345-8 · Cited by 1,654
Mycophenolate mofetil and its mechanisms of action
ALLISON, A. C., & Eugui, E. M. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00188-0 · Cited by 1,433
Self-citationHench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,175
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C. A., Hammond, A. J., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S., Haugen, H. S., Maurer, M. F., Harder, B., Johnston, J. V., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,018
Zheng, L., Nukuna, B. N., Brennan, M., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21109 · Cited by 735
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
The purine path to chemotherapy
Elion, G. B. (1989) · Science · doi:10.1126/science.2649979 · Cited by 687
Prolonged Survival of Human-Kidney Homografts by Immunosuppressive Drug Therapy
Murray, J. E., Merrill, J. P., Harrison, J. H., Wilson, R. E., & Dammin, G. J. (1963) · New England Journal of Medicine · doi:10.1056/nejm196306132682401 · Cited by 550
Research works printed but not linked: 6
- Sandborn WJ., 1996, Am J Gastroenterol, 91, 423
- Allison AC, 1991, Transplant Proc, 23, 10
- Grailer A, 1991, Transplant Proc, 23, 314
- Allison AC, 1993, Transplant Proc, 25, 67
- Laurent AF, 1996, Exp Hematol, 24, 59
- 10.1172/JCI200421109 · DOI
Cited by
Sorted by citations
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
Mycophenolate mofetil in the treatment of uveitis in children
Doycheva, D., Deuter, C., Stuebiger, N., Biester, S., & Zierhut, M. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.094698 · Cited by 106
Mycophenolate Mofetil for the Treatment of Uveitis
Teoh, S. C., Hogan, A. C., Dick, A. D., & Lee, R. W. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.03.004 · Cited by 87
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Llorenç, V., Nakamura, Y., Metea, C., Karstens, L., Molins, B., & Lin, P. (2022) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.63.3.30 · Cited by 20
“8 The intestinal microbiota has recently been investigated as a potential therapeutic target to achieve higher efficacy and lower toxicity of several chemotherapeutic drugs, including MTX. 9,10 Further research in experimental autoimmune uveitis (EAU) demonstrates a strong influence of the gut…”
Metadata
- Authors
- Allison, A.
- Affiliations
- SurroMed, Inc., Menlo Park, CA, USA
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 14
- Issue
- 1_suppl
- Pages
- 2-8
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2074604840
- Cited by
- 480
- References
- 48
- Citations by year
- 2026: 24 · 2025: 35 · 2024: 42 · 2023: 38 · 2022: 56 · 2021: 42 · 2020: 30 · 2019: 18 · 2018: 17 · 2017: 21 · 2016: 23 · 2015: 12 · 2014: 7 · 2013: 16 · 2012: 13
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- mycophenolate mofetil, mycophenolic acid, adhesion molecule expression, tetrahydrobiopterin, nitric oxide, inducible nitric oxide synthase, peroxynitrite, macrophages, anti-inflammatory activity, calcineurin inhibitors, allograft rejection, kidney disease, autoimmune disease, immunosuppression
- MeSH terms
- Azathioprine, B-Lymphocytes, Humans, Immunosuppressive Agents, Mycophenolic Acid, Nitric Oxide, T-Lymphocytes, Vascular Diseases, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
